Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide. Vascular
endothelial growth factor, platelet derived growth factor and the Raf/mitogen‐activated …

AIM: To examine the underlying mechanisms of erlotinib-induced growth inhibition in
hepatocellular carcinoma (HCC). METHODS: Erlotinib-induced alterations in gene …

Mutations affecting the Wnt/β‑catenin pathway have been identified in 26‑40% of
hepatocellular carcinoma (HCC) cases. Aberrant activation of this pathway leads to …

Purpose To compare the clinical outcomes of sorafenib plus either erlotinib or placebo in
patients with advanced hepatocellular carcinoma (HCC) in a multicenter, multinational …

Background Treatment outcome of children with pediatric hepatocellular carcinoma (pHCC)
is poor. Therefore, we evaluated the tyrosine kinase inhibitor sorafenib in a model of pHCC …

ABSTRACT Angiogenesis and RAS/RAF/MEK/ERK pathway have been demonstrated to be
relevant in hepatocellular carcinoma (HCC). Sorafenib, an oral multikinase inhibitor with …

Sorafenib leads to a survival benefit in patients with advanced hepatocellular carcinoma but
its use is hampered by the occurrence of drug resistance. To investigate the molecular …

Sorafenib is currently the medical treatment of reference for hepatocellular carcinoma
(HCC), but it is not known whether sorafenib is equally active in all HCC. Here, our aim was …

Sorafenib is a multi-kinase inhibitor approved for hepatocellular carcinoma, but rarely
causes tumor regression in patients with chronic liver diseases. To investigate whether …

Background Sorafenib is recognized as a standard treatment for advanced hepatocellular
carcinoma (HCC). However, many patients have to adopt dose reduction or terminate the …